{"id":"https://genegraph.clinicalgenome.org/r/7d07fcb7-78e6-455e-8e89-b75f7fdb4628v1.0","type":"EvidenceStrengthAssertion","dc:description":"*EFEMP1* has been a candidate gene for glaucoma since its identification as an extracellular matrix gene regulated at the expression level by TGFÎ²2 in trabecular meshwork cells (PMID: 19450457). It was subsequently identified in a genome-wide association screen as a locus associated with optic disc cup area (PMID: 25631615). Variants in *EFEMP1* were first reported in relation to open-angle glaucoma in 2015, with the publication of a family with multiple affected members showing onset after age 35 years (Mackay et al., PMID: 26162006). Subsequent publications have established that affected individuals may be diagnosed with open-angle glaucoma either during childhood (PMID: 34923728, PMID: 39264138) or in adulthood, and present with ocular hypertension, optic nerve abnormalities including increased vertical cup-to-disc ratio, reduced visual acuity, and/or peripheral visual field constriction. Publications have also linked monoallelic *EFEMP1* variants to the progressive retinal condition Doyne honeycomb degeneration of retina (also known as malattia leventinese, PMID: 10369267). Biallelic *EFEMP1* variants have also been linked to the connective tissue disorder cutis laxa type 1D (PMID: 31792352). Per criteria outlined by the ClinGen Lumping & Splitting Working Group, cases of open-angle glaucoma were found to have a molecular mechanism (monoallelic missense or stop-loss variants with enhanced intracellular or endoplasmic reticulum retention) and mode of inheritance (autosomal dominant) that were distinguishable from the biallelic loss-of-function mechanism of autosomal recessive cutis laxa type 1D. Doyne honeycomb degeneration of retina shares the autosomal dominant mode of inheritance and is also characterized by aberrant intracellular accumulation of EFEMP1 protein in the endoplasmic reticulum (PMID: 34923728), however, it has so far been associated with one particular *EFEMP1* variant (encoding p.Arg345Trp) and has a very distinct phenotype. While one study has found open-angle glaucoma in an affected individual who also shows severe retinal abnormalities (PMID: 39264138), the phenotype is not a sufficiently clear match for Doyne honeycomb degeneration of retina to conclude that the two conditions are part of the same spectrum of disease. Therefore, cases of open-angle glaucoma caused by monoallelic *EFEMP1* variants have been split for curation under a separate disease entity referred to as EFEMP1-related open-angle glaucoma.\n\nEight suspected disease-causing variants in *EFEMP1* have been scored as part of this curation (five missense and three stop-loss). These variants have been collectively reported in nine probands in six publications (PMID: 26162006, PMID: 34923728, PMID: 32476818, PMID: 35946471, PMID: 38083999, PMID: 39264138). All nine probands were heterozygous for their respective variants. Some of these variants have been shown to accumulate intracellularly and/or in the endoplasmic reticulum, and two have been shown to cause disease in animal intravitreal injection models relative to a wild-type control (PMID: 38083999, PMID: 38467175). The mechanism of pathogenicity appears to be monoallelic disruption of EFEMP1 protein localization, possibly leading to loss of retinal ganglion cells (PMID: 38083999).\n\nThis gene-disease association is also supported by expression profiling indicating that *EFEMP1* has an expression pattern similar to other genes associated with early onset glaucoma, with high levels in beam cells, trabecular meshwork-related cells, and cribiform juxtacanalicular cells (PMID: 34923728). *EFEMP1* encodes a glycoprotein component of the extracellular matrix, and functions to contribute to the integrity of basement membrane zones and to anchor other extracellular matrix structures such as elastic fibers to basement membranes. Animal models relevant to open-angle glaucoma are limited to the aforementioned intravitreal injection studies in mice and rats showing progressive increases in intraocular pressure, ganglion cell loss (PMID: 38083999), and increased staining for the extracellular matrix marker fibronectin (PMID: 38467175).\n\nIn summary, *EFEMP1* has moderate evidence of association with EFEMP1-related open-angle glaucoma. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Moderate classification. Additional genetic evidence from cases with *EFEMP1* variants will be required to reach a more definitive classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on December19th, 2024 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/7d07fcb7-78e6-455e-8e89-b75f7fdb4628","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2024-12-19T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2025-01-06T03:29:29.422Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e7d334f-20f0-4bb9-b8ba-0d0bbdc60b4b","type":"EvidenceLine","dc:description":"Up-scoring has been recommended due to localization evidence that the variant is accumulating in the endoplasmic reticulum and showing less localization to the cytoplasm or other intracellular areas, yet is present within cells at 10X normal levels, consistent with the possibility of a toxic variant protein.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e7d334f-20f0-4bb9-b8ba-0d0bbdc60b4b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.238A>T (p.Asn80Tyr) is a missense variant with some evidence of deleterious impact on EFEMP1 function. Localization (PMID: 34923728) seems to be restricted to the ER relative to the wild-type control, while intracellular protein levels are approximately 10X higher than wild-type (PMID: 34923728).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9e7d334f-20f0-4bb9-b8ba-0d0bbdc60b4b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35490425","allele":{"id":"https://genegraph.clinicalgenome.org/r/b82721b2-bfbd-490b-a46a-320333a233db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.238A>T (p.Asn80Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347026882"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/11a09bb5-73bb-49d8-9f1b-0210715808fa","type":"EvidenceLine","dc:description":"Up-scoring is recommended to account for the evidence that the mutant protein is present at an abnormally high level in the intracellular fraction. This is a partial match to other glaucoma-associated EFEMP1 variants (PMID: 34923728).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a09bb5-73bb-49d8-9f1b-0210715808fa_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.418C>T (p.Arg140Trp) is a missense variant with some evidence of deleterious impact on EFEMP1 function. Although secretion (PMID: 33542268) and localization (PMID: 34923728) seem to be normal or near-normal, intracellular protein levels are approximately 5X higher than wild-type (PMID: 34923728).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/11a09bb5-73bb-49d8-9f1b-0210715808fa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26162006","allele":{"id":"https://genegraph.clinicalgenome.org/r/1c63dfcc-fa1d-4776-8567-81b61c2b924c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.418C>T (p.Arg140Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA245997"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e5e0b44-91b6-475c-a012-a0682aa81eab_proband_segregation","type":"FamilyCosegregation","dc:description":"The family exceeds the minimum required number of genotype-positive affected individuals, with only 1 unaffected carrier in the youngest generation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35490425","rdfs:label":"Collantes_2022_Family_A","estimatedLodScore":4.21,"family":{"id":"https://genegraph.clinicalgenome.org/r/3e5e0b44-91b6-475c-a012-a0682aa81eab","type":"Family","rdfs:label":"Collantes_2022_Family_A","member":{"id":"https://genegraph.clinicalgenome.org/r/1ada7032-4e4e-46e8-a08d-e080277b4870","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35490425","rdfs:label":"Collantes_2022_Proband_A-II:10","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":11,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b82721b2-bfbd-490b-a46a-320333a233db"},"detectionMethod":"Genotyping consisted of whole exome sequencing of the proband, followed by Sanger sequencing of the EFEMP1 coding regions in all available family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"The proband has a diagnosis of juvenile primary open-angle glaucoma.","previousTesting":true,"previousTestingDescription":"Previous testing consisted of whole exome sequencing.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9e7d334f-20f0-4bb9-b8ba-0d0bbdc60b4b_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"The patient and affected family members have been diagnosed with juvenile primary open-angle glaucoma. Some but not all family members show elevated intraocular pressure and increased vertical cup:disc ratio.","phenotypeNegativeAlleleNegative":15,"phenotypePositiveAllelePositive":15,"phenotypes":["obo:HP_0007906","obo:HP_0003621","obo:HP_0007663","obo:HP_0031973","obo:HP_0012108"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1ada7032-4e4e-46e8-a08d-e080277b4870"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/bdbd1700-de92-439c-abb1-c4eadcd08275_proband_segregation","type":"FamilyCosegregation","dc:description":"Three family members were genotyped by whole exome capture, identifying the variant in EFEMP1 but no alternative basis for disease in another gene. Other family members were genotyped by Sanger sequencing of PCR products from EFEMP1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26162006","rdfs:label":"Mackay_2015_Family","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/bdbd1700-de92-439c-abb1-c4eadcd08275","type":"Family","rdfs:label":"Mackay_2015_Family","member":{"id":"https://genegraph.clinicalgenome.org/r/8e271b1e-5c75-4cff-bb82-dbeb269f4e7f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26162006","rdfs:label":"Mackay_2015_Family_Proband_II:4","allele":{"id":"https://genegraph.clinicalgenome.org/r/1c63dfcc-fa1d-4776-8567-81b61c2b924c"},"detectionMethod":"Genotypng consisted of whole exome capture trio testing of the proband and two family members (one affected and one unaffected), followed by Sanger sequencing of the EFEMP1 coding regions in all affected family members.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"The proband has a diagnosis of primary open-angle glaucoma. Some but not all family members show visual field abnormalities and/or optic nerve abnormalities, but details for the specific proband are not available.","phenotypes":["obo:HP_0007906","obo:HP_0012108","obo:HP_0003581"],"previousTesting":true,"previousTestingDescription":"Previous testing consisted of whole exome capture trio testing of the proband and two family members (one affected and one unaffected).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/11a09bb5-73bb-49d8-9f1b-0210715808fa_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"The patient and affected family members have been diagnosed with primary open-angle glaucoma. Some but not all family members show visual field abnormalities, optic nerve abnormalities, Bullous keratopathy, and/or age-related cataract.","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0003581","obo:HP_0012108","obo:HP_0007906"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/8e271b1e-5c75-4cff-bb82-dbeb269f4e7f"},"publishedLodScore":4.51,"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/40ad4357-c907-412d-b4e5-cb97804e449e","type":"EvidenceLine","dc:description":"Up-scoring was performed based on the experimental evidence of a functional defect, while down-scoring by 50% was performed to account for the fact that this variant has already been scored in an apparently unrelated proband from the same study.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40ad4357-c907-412d-b4e5-cb97804e449e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.175A>C (p.Met59Leu) is a missense variant with some evidence of deleterious impact on EFEMP1 function. Expression levels appear comparable to wild-type, but the mutant protein shows moderately enhanced intracellular accumulation (PMID: 38083999, Figure 3), accompanied by up-regulation of ER stress markers (PMID:38083999, Figure 4) . There is also a mouse knock-in model that has been scored separately.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/40ad4357-c907-412d-b4e5-cb97804e449e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38083999","allele":{"id":"https://genegraph.clinicalgenome.org/r/8591004c-4575-4c1f-8deb-4c099cef3927","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.175A>C (p.Met59Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347027033"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/f8327403-8d1d-4af8-a6b7-8a20303efc6c","type":"EvidenceLine","dc:description":"Up-scoring has been recommended based on the unrelated patients with similar phenotypes and different stop-loss variants in the same codon.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8327403-8d1d-4af8-a6b7-8a20303efc6c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.1482G>T (p.Ter494Tyr) is a stop-loss variant with no evidence of deleterious impact on EFEMP1 function, although another stop-loss variant in the same codon has restricted localization and intracellular accumulation (PMID: 34923728).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/f8327403-8d1d-4af8-a6b7-8a20303efc6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39264138","allele":{"id":"https://genegraph.clinicalgenome.org/r/20231234-7726-49f1-a85d-899c6b78da88","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.1482G>T (p.Ter494Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347027270"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9aa0782c-b510-49e7-b854-baad1bc6091e","type":"EvidenceLine","dc:description":"Down-scoring has been recommended to account for the diagnosis of Stickler syndrome and the presence of the NM_080629.2(COL11A1):c.857C>T (p.Pro286Leu) variant in the proband and her affected father.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9aa0782c-b510-49e7-b854-baad1bc6091e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35946471","allele":{"id":"https://genegraph.clinicalgenome.org/r/44c30724-a761-4fcf-ab20-be57dc5c3efd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.442C>T (p.Arg148Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA48129455"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a4f6b32f-b5c5-4b1f-9e49-a9674a13254a","type":"EvidenceLine","dc:description":"Up-scoring has been recommended for functional evidence that the variant accumulates intracellularly, with particular localization to the ER. These findings are consistent with other glaucoma-associated variants (PMID: 34923728).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a4f6b32f-b5c5-4b1f-9e49-a9674a13254a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.1480T>C (p.Ter494Gln) is a stop-loss variant with some evidence of deleterious impact on EFEMP1 function. Localization (PMID: 34923728) seems to be restricted to the ER relative to the wild-type control, while intracellular protein levels are approximately 10X higher than wild-type (PMID: 34923728).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a4f6b32f-b5c5-4b1f-9e49-a9674a13254a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35490425","allele":{"id":"https://genegraph.clinicalgenome.org/r/7cadd494-32ea-46fc-8060-5156780e52e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.1480T>C (p.Ter494Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347027276"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e5ba9253-fa60-46e8-9fcd-1a036be323b5","type":"EvidenceLine","dc:description":"Despite the lack of functional data, a different stop-loss variant in the same codon has been reported in a similarly affected patient, with evidence of functional impact on the protein product (PMID: 34923728).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5ba9253-fa60-46e8-9fcd-1a036be323b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32476818","allele":{"id":"https://genegraph.clinicalgenome.org/r/44b99265-6f3e-4584-a0b0-c7962ed2d412","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.1480T>G (p.Ter494Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347027275"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f89e1c23-fe4c-4458-b44f-56ac442c4430","type":"EvidenceLine","dc:description":"Up-scoring has been recommended based on functional evidence that the variant localization is abnormally restricted to the ER and associated with high intracellular accumulation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f89e1c23-fe4c-4458-b44f-56ac442c4430_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.1429C>T (p.Arg477Cys) is a missense variant with some evidence of deleterious impact on EFEMP1 function. Localization (PMID: 34923728) seems to be restricted to the ER relative to the wild-type control, while intracellular protein levels are approximately 10X higher than wild-type (PMID: 34923728).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f89e1c23-fe4c-4458-b44f-56ac442c4430_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35490425","allele":{"id":"https://genegraph.clinicalgenome.org/r/35864da9-3fb7-48b6-a190-9c561a93b3ba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039348.3(EFEMP1):c.1429C>T (p.Arg477Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347027380"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/371253c7-9816-4d55-aa02-a289e499dcba","type":"EvidenceLine","dc:description":"Up-scoring has been recommended based on experimental evidence that the variant has a functional defect resulting in intracellular accumulation and ER stress, which are consistent with observations of other disease-associated variants.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/371253c7-9816-4d55-aa02-a289e499dcba_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001039348.3(EFEMP1):c.175A>C (p.Met59Leu) is a missense variant with some evidence of deleterious impact on EFEMP1 function. Expression levels appear comparable to wild-type, but the mutant protein shows moderately enhanced intracellular accumulation (PMID: 38083999, Figure 3), accompanied by up-regulation of ER stress markers (PMID:38083999, Figure 4) . There is also a mouse knock-in model that has been scored separately.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/371253c7-9816-4d55-aa02-a289e499dcba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38083999","allele":{"id":"https://genegraph.clinicalgenome.org/r/8591004c-4575-4c1f-8deb-4c099cef3927"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":6.75},{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/593b5dc0-bb05-476d-b086-be96cf6a0eb4","type":"EvidenceLine","dc:description":"The injection-facilitated model is not as informative as a knock-in mouse, and the group expressed some concerns about the overexpression design and the potential for variability in volume-related effects due to injection itself. At the same time, some enhanced scoring has been recommended based on the use of a disease-associated mutant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d45e823f-5f80-45b4-9b7f-6dc1cdf6606b","type":"Finding","dc:description":"The mouse injected with the glaucoma-associated EFEMP1 variant exhibited progressive increase in intraocular pressure over the course of 6 weeks post-injection (Figure 5A). Staining for the retinal ganglion cell marker Tuj showed loss of this cell type (generally associated with glaucoma, Figure 5C).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38083999","rdfs:label":"Mouse eyes injected with EFEMP1 mutant","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/5578c106-e5c4-4057-8b70-5a77ebff999c","type":"EvidenceLine","dc:description":"While the injection-facilitated model is not as informative as a knock-in animal, and some down-scoring was recommended due to the overexpression design and the potential for volume of injection effects, scoring has been recommended based on the use of a disease-associated mutant and the phenotypic match to the human patients.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/653b7525-7f62-4f99-82b0-af9f4e9616a9","type":"Finding","dc:description":"The rat injected with the glaucoma-associated EFEMP1 variant exhibited progressive increase in intraocular pressure over the course of 3 weeks post-injection (Figure 6C). Staining for the extracellular matrix marker fibronectin showed increase with overexpression of the mutant (opposite from the wild-type, Figure 6D).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38467175","rdfs:label":"Overexpression of wild-type or mutant EFEMP1 in rat eyes","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/0363f777-b1d5-4c74-bee3-0bd783cf1db2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2d42b7c-d66b-46f8-a6e0-2debdd0460ad","type":"EvidenceLine","dc:description":"This data matches the expression pattern of other glaucoma-associated genes.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/63558d4c-447b-4a82-946c-cab2fc790212","type":"Finding","dc:description":"Single cell RNA-seq indicates that wild-type EFEMP1 expression patterns within cells of the eye match those of other glaucoma-related genes, including their highest levels in the trabecular meshwork beam cells and juxtacanilicular matrix cells (Figure 3).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34923728","rdfs:label":"EFEMP1 expressed in cells from aqueous humor outflow pathway","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.75}],"evidenceStrength":"Moderate","sequence":9701,"specifiedBy":"GeneValidityCriteria11","strengthScore":8.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/sahsFTal7FM","type":"GeneValidityProposition","disease":"obo:MONDO_0005338","gene":"hgnc:3218","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0363f777-b1d5-4c74-bee3-0bd783cf1db2-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}